Biogen Says European Commission Revokes Marketing Authorizations For Generic Versions Of TECFIDERA

RTTNews | 372 days ago
Stocktwits
Biogen Says European Commission Revokes Marketing Authorizations For Generic Versions Of TECFIDERA

(RTTNews) - Biotechnology company Biogen, Inc. (BIIB) announced Tuesday that the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen's product TECFIDERA (dimethyl fumarate) held by Accord, Mylan, Neuraxpharm, Polpharma and Teva.

In reaching this decision, the European Commission affirmed that Biogen is entitled to full data protection and marketing protection for TECFIDERA.

Biogen said this decision confirms to the laws governing data exclusivity and marketing protection which are essential to protecting innovation.

TECFIDERA is entitled to marketing protection until February 3, 2025, and is the only dimethyl fumarate treatment for multiple sclerosis that may be lawfully placed on the market for sale in the EU until that date.

Biogen has initiated legal action to defend its market protection rights and has sufficient supply of TECFIDERA to supply the entire European market.

Tags: BIIB
Stocktwits
read more
Biogen Q2 Results Top Estimates; Boosts FY24 Outlook

Biogen Q2 Results Top Estimates; Boosts FY24 Outlook

Biotechnology company Biogen Inc. (BIIB) reported Thursday net income attributable to the company for the second quarter of $583.6 million or $4.00 per share, higher than $591.6 million or $4.07 per share in the prior-year quarter.
RTTNews | 146 days ago
Biogen To Buy Human Immunology Biosciences In Deal Valued At Up To $1.8 Bln

Biogen To Buy Human Immunology Biosciences In Deal Valued At Up To $1.8 Bln

Biogen Inc. (BIIB) and privately-held biotechnology company Human Immunology Biosciences or HI-Bio, announced Wednesday the companies have entered into a definitive agreement under which Biogen has agreed to acquire HI-Bio for $1.15 billion upfront and up to $650 million in potential milestone payments.
RTTNews | 217 days ago
Biogen Q2 Results Top Estimates; Backs FY23 Outlook

Biogen Q2 Results Top Estimates; Backs FY23 Outlook

Biotechnology company Biogen, Inc. (BIIB) reported Tuesday that net income attributable to the company for the second quarter plunged to $591.6 million or $4.07 per share from $1.06 billion or $7.24 per share in the prior-year quarter.
RTTNews | 519 days ago
Biogen Q1 Results Top Estimates; Reaffirms FY23 Outlook

Biogen Q1 Results Top Estimates; Reaffirms FY23 Outlook

Biotechnology company Biogen Inc. (BIIB) reported Tuesday net income attributable to the company for the first quarter of $387.9 million or $2.67 per share, higher than $303.8 million or $2.06 per share in the prior-year quarter.
RTTNews | 610 days ago
Biogen Q4 Results Top Estimates

Biogen Q4 Results Top Estimates

Biotechnology company Biogen Inc. reported Wednesday that profit for the fourth quarter surged 50 percent from last year, reflecting lower expenses despite a 7 percent revenue growth. However, adjusted earnings per share and quarterly revenues topped analysts' expectations. The company also initiated adjusted earnings and revenue growth guidance for the full-year 2023, in line with estimates.
RTTNews | 679 days ago
Biogen Appoints Christopher Viehbacher As President And CEO

Biogen Appoints Christopher Viehbacher As President And CEO

Biotechnology company Biogen Inc. (BIIB) announced Thursday that its Board of Directors has appointed Christopher Viehbacher as President and Chief Executive Officer and a member of the Board of Directors, effective November 14. Viehbacher succeeds Michel Vounatsos, who has led the company since 2017.
RTTNews | 776 days ago
Tools
Economic Calendar
Market Hours
Interest Rates
Holidays Calendar
Forex Market
Forex Volatility
Forex Correlation
Forex News
forex analysis
COT Data
Liquidity
Forex Calculators
Forex Heat Map
Indicators Heatmap
Community
Community
Systems
Most Popular Systems
Strategies
Contests
Forex Charts
Forex Sentiment
Sentiment Indicator
Reviews
Brokers
Prop Trading Firms
VPS Services
Signal Providers
EA Programming Services
Affiliate Programs
PAMM Broker Services
Rebate Program Services
Trading Platforms
Expert Advisors
Crypto Exchanges
Trading Courses
Brokers
Forex Spreads
Forex Broker Quotes
Forex Broker Swaps
Forex Broker Volume
Forex Broker Promotions Broker News
Platform
Widgets
Features
API
RSS
Stock Portfolio
Affiliate Software
Advanced Charts
Support
FAQ
Help
Contact Us
Report a Bug!
About
Blog
© 2024 Myfxbook Ltd. All Rights Reserved.
HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.